A Randomized Phase II Trial to Assess the Efficacy and Safety of Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy
A randomized phase II trial to assess the efficacy and safety of selective metabolically
adaptive radiation dose escalation in locally advanced non-small cell lung cancer receiving
definitive chemoradiotherapy. Eligible and consenting patients will be randomized to receive
conventional chemoradiotherapy or chemoradiotherapy with a radiation (RT) integrated boost.
All patients will receive a fludeoxyglucose-positron emission tomography (FDG-PET) scan
within two weeks prior to starting treatment. The primary outcome is to determine if dose
escalation to metabolically active tumour subvolumes will reduce local-regional failure rate
at 2 years.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society